SCHEMBL13627002

SCHEMBL13627002

Cc1c(C(C)(C)C)cc(C(C)(C)C)c(OPOc2ccc3ccccc3c2)c1-c1c(C)c(C(C)(C)C)cc(C(C)(C)C)c1OPOc1ccc2ccccc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 3/20 0.38
CYP1A2 P05177 2/20 0.38
ENPP3 O14638 1/20 0.34
ALPL P05186 1/20 0.34
ENPP1 P22413 1/20 0.34
XIAP P98170 1/20 0.34
ALOX5 P09917 4/20 0.33
TDP1 Q9NUW8 2/20 0.33
AGXT P21549 2/20 0.32
ALDH1A1 P00352 2/20 0.32
HPGD P15428 2/20 0.32
ALOX15 P16050 1/20 0.32
HSD17B10 Q99714 1/20 0.32
KDM4E B2RXH2 2/20 0.31
MAPK1 P28482 1/20 0.31
MEN1 O00255 1/20 0.31
GLA P06280 1/20 0.31
GAA P10253 1/20 0.31
MAPT P10636 1/20 0.31
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13627007 0.87 TNFRSF1A (0.30)
SCHEMBL7207043 0.80 CYP2A6 (0.37) CYP2A6CYP1A2ENPP3ALPLENPP1
SCHEMBL13627003 0.78 ALDH1A1 (0.37) CYP1A2ALOX5TDP1ALDH1A1HSD17B10
SCHEMBL13627009 0.78 CYP1A2 (0.38) CYP2A6CYP1A2ENPP3ALPLENPP1
SCHEMBL13626998 0.77 CYP1A2 (0.47) CYP2A6CYP1A2ALOX5TDP1ALDH1A1
SCHEMBL16705219 0.73 CYP2A6 (0.58) CYP2A6CYP1A2ALOX5TDP1AGXT
SCHEMBL13291473 0.70 GABRA1 (0.30)
SCHEMBL14452714 0.68 KDM4E (0.32) ALDH1A1HSD17B10KDM4E
SCHEMBL13627001 0.67
SCHEMBL7206268 0.64 ALDH1A1 (0.36) CYP1A2ALOX5TDP1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615645-B2 Method for the continuous production of aldehydes BASF AKTIENGESELLSCHAFT (DE) 2009-11-10 US disclosed
US-7241857-B2 Method for producing allyl compound, and ether or ester compound produced thereby MITSUBISHI CHEMICAL CORPORATION (JP) 2007-07-10 US disclosed
US-20070083066-A1 Method for the production of 1,7-octadiene and use thereof BASF AKTIENGESELLSCHAFT (DE) 2007-04-12 US disclosed
US-7173157-B2 Method for producing an allyl compound MITSUBISHI CHEMICAL CORPORATION (JP) 2007-02-06 US disclosed
US-20070004939-A1 Method for the continuous production of aldehydes VOLLAND MARTIN 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004939-A1 Method for the continuous production of aldehydes HRH4, HRH2, HRH3 CYP2A6 207/4885CYP1A2 157/4885ENPP3 3133/4885
US-20070083066-A1 Method for the production of 1,7-octadiene and use thereof CYP51A1, MSMO1, HSD17B7 CYP2A6 57/4885CYP1A2 33/4885ENPP3 2920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.